Cingulate, Inc. (CING)

NASDAQ: CING · IEX Real-Time Price · USD
2.60 0.14 (5.69%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap27.86M
Revenue (ttm)n/a
Net Income (ttm)-5.10M
Shares Out10.71M
EPS (ttm)-0.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume179,577
Open2.48
Previous Close2.46
Day's Range2.43 - 2.62
52-Week Range2.20 - 5.15
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About CING

Cingulate is a clinical stage biopharmaceutical company using our proprietary Precision Timed Release, or PTR, drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. We are initially focusing our efforts on the treatment of Attention Deficit/Hyperactivity Disorder, or ADHD. Our PTR platform incorporates a proprietary Ero...

IndustryBiotechnology
IPO DateDec 8, 2021
CEOShane J. Schaffer
Employees13
Stock ExchangeNASDAQ
Ticker SymbolCING
Full Company Profile

Financial Performance

Financial Statements

News

Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Ci...

NEW YORK, NY / ACCESSWIRE / December 10, 2021 / Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQ:CING). Cingulate...

1 month ago - Accesswire

Cingulate Inc. Announces Closing of Initial Public Offering

KANSAS CITY, Kan., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) d...

1 month ago - GlobeNewsWire

Cingulate Inc. Announces Pricing of $25.0 Million Initial Public Offering

KANSAS CITY, Kan., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) d...

1 month ago - GlobeNewsWire